AstraZeneca's Imfinzi, Lynparza On Track To India Debut
AstraZeneca, which recently committed to scaling up investments in India, appears on course to bringing two key new anticancers to the country, including the PD-1/L1 inhibitor Imfinzi. Pricing aspects for the products in what is a largely out-of-pocket market are, however, expected to be decisive.
You may also be interested in...
The price factor could potentially shrink the patient pool in first line non-small cell lung cancer for Tagrisso in largely out-of-pocket markets like India, though AstraZeneca has put in place a patient assistance program in this market for those can’t afford the medicine.
Are drug firms being lax when it comes to Phase IV studies in markets like India or are certain arbitrarily determined regulatory requirements largely to blame? Scrip delves into the issue.
AstraZeneca expects to invest $90m over five years to shore up its footprint in India – a market where the Anglo-Swedish major has introduced a string of new products but has also had a fair share of challenges.